What the Section 301 Tariff Means for Indian Shipments to the US

The United States has imposed an additional 10% duty on most imports from India under Section 301 of the Trade Act, as part of a wider campaign targeting forced labour in global supply chains. The levy comes on top of existing US customs duties, increasing the landed cost of Indian goods in the American market.

While the action has triggered worry among exporters, it is not a determination that Indian products are made with forced labour. India was placed in the lower tariff tier after introducing policy measures to strengthen its legal framework, while several competing nations face higher duties. This means that labour-intensive industries such as textiles, garments and leather products are not automatically uncompetitive: buyers comparing Indian goods with those from Bangladesh, Vietnam or other South Asian suppliers will often encounter similar total tariff burdens.

Pharmaceutical products and ingredients, meanwhile, appear largely insulated because many fall under the exemption framework. Exporters, however, are urged to verify product-specific classifications rather than relying on blanket exemptions.

Sector-by-Sector: Where Indian Exporters Gain and Lose Ground

The Competitive Matrix: Why Textiles and Leather Are Not Isolated

The true impact on India’s export competitiveness depends on the relative tariff treatment of its rivals. Because many competitor nations—especially in South Asia—face similar or higher Section 301 duties, the 10% levy does not necessarily erode India’s price advantage. The playing field remains relatively level for garment and leather suppliers, who often compete on already narrow margins. The challenge lies more in managing the immediate cash-flow pressure of the added duty when US buyers attempt to renegotiate contracts or push for cost absorption.

Where Pharmaceuticals Stand Out

The pharmaceutical sector emerges as a clear beneficiary of the exemption language that covers a wide array of active ingredients and finished formulations. This carve-out limits direct landed-cost increases, offering greater pricing stability and shielding India’s substantial pharma export flows to the US. However, companies should confirm the exact Harmonized Tariff Schedule classifications because the exemptions are product-specific, not universal.

The Hidden Cost: Compliance and Supply Chain Scrutiny

Beyond the percentage points, the new measure is likely to intensify American buyers’ focus on supply chain transparency. The forced-labour basis of Section 301 means importers will demand more rigorous documentation. Indian exporters with robust environmental, social and governance (ESG) practices and fully traceable supply chains could gain an edge—turning a regulatory burden into a commercial differentiator. The absence of such documentation, though, invites reputational risk and may accelerate contract reviews.

Three Moves Indian Exporters Must Make Now

  • Map your exact tariff exposure. Check the product-specific Harmonized Tariff Schedule code for each SKU. Determine whether any Section 301 exemptions apply, and calculate the total landed duty including normal customs duties, the new 10% levy, and any other trade remedies.
  • Audit existing contracts immediately. Identify who bears responsibility for additional duties under current supply agreements. Use the review to renegotiate balanced arrangements—partial cost sharing, larger order commitments, or longer-term contracts—rather than simply absorbing the margin hit.
  • Strengthen supply chain documentation. Prepare auditable records proving labour practices and raw-material origins. Proactively sharing this data with US buyers can foster trust and mitigate the reputational risk arising from the forced-labour scrutiny that underpins Section 301.

Risk & Opportunity Assessment

Commercial RiskHighThe 10% duty raises landed costs for all non-exempt Indian goods, squeezing margins in low-margin sectors like textiles and leather, especially when US importers demand price concessions.
Competitive RiskMediumMost rival South Asian suppliers face similar or higher Section 301 tariffs, so India’s relative price competitiveness remains broadly intact, but any future diverging tariff adjustments could tip the balance.
Regulatory RiskHighThe new Section 301 tariff is an active trade measure that can be modified or expanded. Exporters also face compliance risk if they misclassify products or if exemptions are incorrectly applied.
Reputation RiskMediumThe forced-labour linkage means US buyers will scrutinise supply chains more closely. Indian companies without transparent ESG records could lose orders or face contract renegotiations.
Technology DisruptionLowNo significant technology shift is directly associated with the tariff action.
Commercial OpportunityLowWhile exporters with strong compliance can differentiate themselves, the tariff acts primarily as a cost headwind, and pharma exemptions—though beneficial—reflect a defensive rather than growth opportunity.